Parker Institute for Cancer Immunotherapy posted on X:
“Turning all cancers into curable diseases takes urgency, bold ideas and relentless drive. To advance that mission, we’re proud to share that Ira Mellman, PhD, has joined PICI as President of Research.
A leader in cancer immunology, Dr. Mellman helped shape therapies like Tecentriq, anti-TIGIT and personalized vaccines at Genentech. His research at Yale laid the groundwork for principles still guiding the field today.
At PICI, he’ll leverage his deep scientific expertise to support our network and help move the science faster, and further, toward cures.”
